Back to search results

Pilot Study of Paricalcitol for Chronic Pancreatitis

This pilot study is testing a medication called paricalcitol to see if it's practical and acceptable for adults with chronic pancreatitis (ongoing inflammation of the pancreas). Researchers want to see if paricalcitol can improve your health-related quality of life. The study will also look at imaging and lab tests. You might be able to join if you are between 18 and 75 years old and have chronic pancreatitis not caused by gallstones. This study aims to enroll 24 participants, but its current recruitment status is unclear.

Study design
This is an interventional study, meaning participants will receive either paricalcitol or a placebo (an inactive substance that looks like the study drug). It plans to enroll 24 participants.
What's involved
You would have medical history and medication reviews, routine lab tests, and MRI and DEXA scans at the beginning and end of the study. Mechanistic specimens will be collected at screening, month 6, and month 12.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at the end of the study (12 months).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05664880

A PiLot ClinicaL TrIal of ParicAlcitol for ChroNiC PancrEatitis

Active, Not Recruiting
EARLY_PHASE1Ages 18–75InterventionalTreatment
Cedars-Sinai Medical Center
~24 participants
Updated 2026-08-05 on ClinicalTrials.gov
What's tested:ParicalcitolPlacebo

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Examine the feasibility of testing the effect of paricalcitol on health-related quality of life in patients with chronic pancreatitis
Measured over End of study (12 Months)

Conditions

Chronic Pancreatitis

Explore related trials

Chronic Pancreatitis

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Stephen Pandol, MD · PRINCIPAL_INVESTIGATOR · Cedars-Sinai Medical Center

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study
Male or female, aged 18-75 at time of enrollment
Diagnosis of Chronic Pancreatitis episode is not attributable to gallstones (i.e. suspected or definite biliary etiology), medications, trauma or autoimmune pancreatitis.
Ability to take oral medication and be willing to adhere to the dosing regimen
Normal Calcium levels- 8.5 to 10.2 mg/dL
Normal Phosphate levels- 2.8 to 4.5 mg/dL
Normal Parathyroid hormone levels- 10 to 65 pg/mL
For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 1 week after the end of Investigational Product administration
For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner
No prior pancreatic surgery
Pancreatic necrosis, if present, is \<50% (to be verified by radiologist)
No involvement in any interventional trials currently or within 6 months of enrollment
Participants must not have medical or psychiatric illnesses or ongoing substance abuse that in the investigator's opinion would compromise their ability to tolerate study interventions or participate in longitudinal follow up
Patients with known abnormal creatinine (GFR \< 30) or renal failure (applies to patients with chronic upper abdominal pain of suspected pancreatic origin and suspected CP.
Known Pregnancy. All participants of childbearing potential, except if post-menopausal \[i.e. no menses for ≥2 years\] or had a hysterectomy, bilateral tubal ligation/clip (surgical sterilization) or surgical removal of both the ovaries), must have a negative urine or serum B-HCG pregnancy test documented within 2 days prior to any endoscopic or radiologic procedures done for research purposes. Any standard of care tests will follow institutional policies regarding pregnancy test
Currently incarcerated
Inability to tolerate MRI

Exclusion

Pregnancy or lactation
History of autoimmune or traumatic pancreatitis, or sentinel attack of acute necrotizing pancreatitis which results in suspected disconnected duct syndrome
Primary pancreatic tumors - pancreatic ductal adenocarcinoma, suspected cystic neoplasm (\>1 cms in size or main duct involvement), neuroendocrine tumors, and other uncommon tumors.
Pancreatic metastasis from other malignancies
History of solid organ transplant, HIV/AIDS.
Abnormal lab values: calcium, phosphate, or parathyroid hormone

What this trial measures

  • Examine the feasibility of testing the effect of paricalcitol on health-related quality of life in patients with chronic pancreatitisEnd of study (12 Months)

    The proposed trial will examine the feasibility of testing the effect of the vitamin D analogue called paricalcitol (also known as Zemplar), on health-related quality of life, imaging, and biomarkers in patients with chronic pancreatitis (CP). Health-related quality of life measurements will be collected via questionnaires to assess overall health, quality of life, and pain. An Acceptability Form will be provided during the last visit to gauge the general acceptability of the intervention. Feasibility will be met if ≥75% of enrolled patients complete the 12-month study. There will be a 21-month recruitment period and a one-year treatment period.